HEPSA
Local cover image
Local cover image

Early treatment consideration in patients with hepatitis B ‘e’ antigen-positive chronic infection: is it time for a paradigm shift?

By: Series: Viruses ; Vol. 4 (5)Basel SWI MDPI 2022Description: 12pSubject(s): Online resources: Summary: To date, antiviral therapy has been reserved for patients with ostensibly active liver disease, fibrosis or cirrhosis, and/or increased risk of HCC. Historically, patients with hepatitis B ‘e’ antigen (HBeAg)-positive chronic infection, were not offered antiviral therapy. The current review discusses the reasons to consider early antiviral therapy in HBeAg-positive chronic infection. Related terms Hep B, HBV.
Tags from this library: No tags from this library for this title.
Holdings
Item type Current library Call number Status Date due Barcode
Online journal/article Library Online Available

Available in: English

To date, antiviral therapy has been reserved for patients with ostensibly active liver disease, fibrosis or cirrhosis, and/or increased risk of HCC. Historically, patients with hepatitis B ‘e’ antigen (HBeAg)-positive chronic infection, were not offered antiviral therapy. The current review discusses the reasons to consider early antiviral therapy in HBeAg-positive chronic infection.

Related terms Hep B, HBV.

Click on an image to view it in the image viewer

Local cover image